Advanced Enzyme Technologies Limited

NSEI:ADVENZYMES 주식 리포트

시가총액: ₹38.9b

Advanced Enzyme Technologies 배당 및 자사주 매입

배당 기준 점검 4/6

Advanced Enzyme Technologies 수익으로 충분히 충당되는 현재 수익률 1.5% 보유한 배당금 지급 회사입니다.

핵심 정보

1.5%

배당 수익률

-0.02%

자사주 매입 수익률

총 주주 수익률1.5%
미래 배당 수익률2.1%
배당 성장률22.6%
다음 배당 지급일n/a
배당락일n/a
주당 배당금n/a
배당 성향38%

최근 배당 및 자사주 매입 업데이트

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20

Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20

Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20

Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20

Recent updates

ADVENZYMES: Steady Risk And Margins Will Support Future Upside

Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.

ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside

Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.

ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside

Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.

ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside

Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.

ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside

Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).

ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares

Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).

Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up

Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up

Preventive Health And Green Chemistry Will Expand Future Markets

Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.

Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital

Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20

Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20

Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20

Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20

Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?

Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?

After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting

May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting

Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture

Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture

The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?

Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 18
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 배당금 지급이 안정적인 반면, ADVENZYMES 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.

배당금 증가: ADVENZYMES 의 배당금 지급이 증가했지만 회사는 9 년 동안만 배당금을 지급했습니다.

배당 수익률 vs 시장

Advanced Enzyme Technologies 배당 수익률 vs 시장
ADVENZYMES의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (ADVENZYMES)1.5%
시장 하위 25% (IN)0.3%
시장 상위 25% (IN)1.5%
업계 평균 (Chemicals)0.8%
분석가 예측 (ADVENZYMES) (최대 3년)2.1%

주목할만한 배당금: ADVENZYMES 의 배당금( 1.5% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.29% )보다 높습니다.

고배당: ADVENZYMES 의 배당금( 1.5% )은 Indian 시장( 1.48% )

주주 대상 이익 배당

수익 보장: 합리적으로 낮은 지불 비율 ( 38.2% )로 ADVENZYMES 의 배당금 지급은 수익으로 충분히 충당됩니다.

주주 현금 배당

현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 44% )로 ADVENZYMES 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/01 14:59
종가2026/04/30 00:00
수익2025/12/31
연간 수익2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Advanced Enzyme Technologies Limited는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Nandan ChakrabortyAxis Capital Limited
Abhishek NavalgundCentrum Broking Limited
null nullDBS Bank Ltd